pasritamig

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
pasritamig

GtoPdb Ligand ID: 14352

Synonyms: JNJ-78278343 | JNJ78278343

Compound class: Antibody

Comment: Pasritamig (JNJ-78278343) is a bispecific kallikrein related peptidase 2 (KLK2)/CD3e monoclonal antibody. It acts as a T-cell engager targeting KLK2 on tumour cells.
The peptide sequences for the heavy and light chains of pasritamig's KLK2 binding domain are claimed in patent US11965024B2 [1] and are a component of the antibody named KL2B30. The anti-cD3e component is claimed in patent US11827708B2 [2].

References
1. Ganesan R, Grewal IS, Singh S, Hansen MR. (2024) Methods and compositions for modulating beta chain mediated immunity. Patent number: US11965024B2. Assignee: Janssen Biotech Inc. Priority date: 10/09/2021. Publication date: 23/04/2024.
2. Obermajer N, Zwolak A, Laquerre S, De Lange D, Hasler J, Versmissen S, Petley TD, van de Ven K, Yi K, Singh S et al.. (2023) Proteins comprising HLA-G antigen binding domains and their uses. Patent number: US11827708B2. Assignee: anssen Pharmaceutica NV, Janssen Biotech Inc. Priority date: 29/07/2021. Publication date: 28/11/2023.
3. Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville JL et al.. (2025) Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. J Clin Oncol, 43 (22): 2515-2526. [PMID:40450573]

References

1. Ganesan R, Grewal IS, Singh S, Hansen MR. (2024)
Methods and compositions for modulating beta chain mediated immunity.
Patent number: US11965024B2. Assignee: Janssen Biotech Inc. Priority date: 10/09/2021. Publication date: 23/04/2024.

2. Obermajer N, Zwolak A, Laquerre S, De Lange D, Hasler J, Versmissen S, Petley TD, van de Ven K, Yi K, Singh S et al.. (2023)
Proteins comprising HLA-G antigen binding domains and their uses.
Patent number: US11827708B2. Assignee: anssen Pharmaceutica NV, Janssen Biotech Inc. Priority date: 29/07/2021. Publication date: 28/11/2023.

3. Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville JL et al.. (2025)
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
J Clin Oncol, 43 (22): 2515-2526. [PMID:40450573]